Supplier log in
Future Procurement Opportunity (FPO) - Supply of Bevacizumab
Details
|
Tender Closed
|
|
| RFx ID : | 29939939 |
| Tender Name : | Future Procurement Opportunity (FPO) - Supply of Bevacizumab |
| Reference # : | |
| Open Date : | Q3 2024 |
| Indicative RFx Release Date : | Q3 2024 [?] |
| Tender Type : | Future Procurement Opportunity (FPO) |
| Project Status : | Initial development [?] |
| Indicative Total Value : | $5M - $10M [?] |
| Expected number of contracts offered : | 1 |
| Tender Coverage : | Sole Agency [?] |
| Categories : |
|
| Regions: |
|
| Required Pre-qualifications : | None |
| Contact : |
Pharmac Procurement Team procurement@Pharmac.govt.nz . |
| Related Tenders: | |
Pharmac is planning on issuing a competitive process for supply of bevacizumab.
Bevacizumab is currently funded for recurrent respiratory papillomatosis, ocular neovascularisation and exudative ocular angiopathy in Health NZ Hospitals. The current eligibility criteria for bevacizumab can be found here: https://schedule.pharmac.govt.nz/HMLOnline.php?edition=&osq=bevacizumab
This competitive process may result in additional funded indications. It may, or may not, also result in widened access to the current criteria.
The Pharmaceutical Schedule is a list of funded medicines in the community and/or that can be used in Health New Zealand | Te Whatu Ora hospitals. More information on the Schedule can be found here: https://pharmac.govt.nz/pharmaceutical-schedule/about-the-schedule
Funding applications for bevacizumab currently under consideration can be found on the Pharmac Application Tracker (https://connect.pharmac.govt.nz/apptracker/s/global-search/Bevacizumab). Links to specific funding proposals under consideration are provided below.
Bevacizumab used in the treatment of hepatocellular carcinoma:
• Proposal: P-001618 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000AlzxU/p001618)
Bevacizumab used in the treatment of colorectal cancer:
• Proposal: P-000055 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptpo/p000055)
Bevacizumab used in the treatment of glioma:
• Proposal: P-000265 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptvh/p000265)
• Proposal: P-000740 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puCg/p000740)
Bevacizumab used in the treatment of ovarian cancer:
• Proposal: P-001366 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pufP/p001366)
• Proposal: P-001803 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BTk6R/p001803)
Bevacizumab used in the treatment of cervical cancer:
• Proposal: P-000311 (https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptxU/p000311)
